Hyperbilirubinæmi, fortrinsvis rapporteret som forhøjet indirekte bilirubin, er observeret hos 14% af patienterne under behandling med indinavir.
Hyperbilirubinaemia, reported predominantly as elevated indirect bilirubin, has occurred in 14% of patients during treatment with indinavir.